A detailed history of Lindbrook Capital, LLC transactions in Morpho Sys Ag stock. As of the latest transaction made, Lindbrook Capital, LLC holds 1,248 shares of MOR stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,248
Previous 1,256 0.64%
Holding current value
$0
Previous $22,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$0.0 - $18.96 $0 - $151
-8 Reduced 0.64%
1,248 $0
Q2 2024

Jul 31, 2024

BUY
$17.36 - $19.34 $138 - $154
8 Added 0.64%
1,256 $22,000
Q1 2024

Apr 25, 2024

BUY
$8.6 - $18.18 $825 - $1,745
96 Added 8.33%
1,248 $22,000
Q4 2023

Jan 31, 2024

SELL
$4.55 - $9.9 $309 - $673
-68 Reduced 5.57%
1,152 $11,000
Q3 2023

Oct 25, 2023

BUY
$6.72 - $8.6 $456 - $584
68 Added 5.9%
1,220 $8,000
Q1 2023

Apr 26, 2023

SELL
$3.56 - $5.22 $1,053 - $1,545
-296 Reduced 20.44%
1,152 $4,000
Q4 2022

Jan 24, 2023

BUY
$3.21 - $5.74 $4,648 - $8,311
1,448 New
1,448 $0
Q2 2022

Aug 01, 2022

BUY
$4.51 - $7.39 $15,550 - $25,480
3,448 New
3,448 $17,000
Q1 2020

Apr 22, 2020

SELL
$18.86 - $37.36 $2,187 - $4,333
-116 Closed
0 $0
Q2 2019

Jul 24, 2019

BUY
$23.24 - $26.76 $2,695 - $3,104
116 New
116 $2,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.